<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Besides the insulinotropic effects of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) mimetics, their effects on <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> are of interest </plain></SENT>
<SENT sid="1" pm="."><plain>No previous study has investigated associations between plasma levels of GLP-1 and CHD </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We investigated longitudinal relationships of fasting GLP-1 with the dynamic GLP-1 response after OGTT (difference between 60 min OGTT-stimulated and fasting GLP-1 levels [DeltaGLP-1]) and CHD in a population-based cohort of 71-year-old men </plain></SENT>
<SENT sid="3" pm="."><plain>In the same cohort, we also cross-sectionally investigated the association between stimulated GLP-1 levels and: (1) <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> (blood pressure, <z:chebi fb="23" ids="18059">lipids</z:chebi>, urinary albumin, waist circumference and insulin sensitivity index [M/I] assessed by euglycaemic-hyperinsulinaemic clamp); and (2) <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During the follow-up period (maximum 13.8 years), of 294 participants with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT), 69 experienced a CHD event (13.8 years), as did 42 of 141 with IGT and 32 of 74 with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>DeltaGLP-1 did not predict CHD (HR 1.0, 95% CI 0.52-2.28) </plain></SENT>
<SENT sid="6" pm="."><plain>The prevalence of IGT was associated with DeltaGLP-1, lowest vs highest quartile (OR 0.3, 95% CI 0.12-0.58), with no such association for type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (OR 1.0, 95% CI 0.38-2.86) </plain></SENT>
<SENT sid="7" pm="."><plain>M/I was significantly associated with DeltaGLP-1 in the type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> group (r = 0.38, p &lt; 0.01), but not in the IGT (r = 0.11, p = 0.28) or NGT (r = 0.10, p = 0.16) groups </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: Impaired GLP-1 secretion is associated with IGT, but not with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>This finding in the latter group might be confounded by oral <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering treatment </plain></SENT>
<SENT sid="10" pm="."><plain>GLP-1 does not predict CHD </plain></SENT>
<SENT sid="11" pm="."><plain>Although DeltaGLP-1 was associated with insulin sensitivity in the type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> group, GLP-1 does not seem to be a predictor of CHD in insulin-resistant patients </plain></SENT>
</text></document>